March 2022 – The Second Edition of Radiotheranostics Today is out!
Today we celebrate the 81st anniversary of the first radioiodine [...]
Lu-177-PSMA-617 approved by FDA for prostate cancer patients
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
Novel Radioligand Proven Superior for Metastatic Prostate Cancer
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients [...]
Rare is Many
Do you know that there are 300 million people worldwide [...]
World NGO Day 2022
Each year on February 27th, a diverse array of supporters [...]
Today is the World Cancer Day
Today is World Cancer Day and this year’s theme led [...]
Estimate the anticipated benefit from Lutetium-177-DOTATATE
External Validation of a Clinical Score for Patients With Neuroendocrine [...]
Theranostics: A Smart Bomb for Cancer
MSK News/MSK News Winter 2021/2022 In the basement of the [...]
Encouraging Early Results for Prostate Cancer Screening
Dosing of First Patients Shows Encouraging Early Results in the [...]
Warm and Hopeful Wishes 2022
Getting into 2022 with a lot of things to do! [...]